Study Title

claritypharmaceuticals

Positron Emission Tomography Using 64Cu-SAR-bisPSMA in Participants With High-risk Prostate Cancer Prior to Radical Prostatectomy: A Prospective, Single-arm, Multi-center, Blinded-review, Phase 3 Diagnostic Performance Study

Study Details

Description:

The aim for this study is to assess the diagnostic performance of 64Cu-SAR-bisPSMA PET to detect regional nodal metastases.

Sponsor:

Clarity Pharmaceuticals

Contacts:

Clarity Pharmaceuticals

clinicaltrials@claritypharmaceuticals.com

+61 (0) 2 9209 4037

Government Study Link:

NCT06056830 - Click here to see study on

ClinicalTrials.gov

Inclusion
  • • High-risk or greater PC defined by National Comprehensive Cancer Network Guidelines Version 1.2023
  • • Untreated, histologically confirmed adenocarcinoma of the prostate
  • • Patients electing to undergo RP with PLND.
Exclusion
  • •Any serious medical condition or extenuating circumstance which the investigator feels may interfere with the procedure
  • •Patients with known predominant small cell or neuroendocrine PC

Patient Education

Patient Education Not Yet Provided

Publications

Publications Not Yet Provided

Locations

United States

XCancer - Omaha

17607 Gold Plaza, Omaha, Nebraska 68130, United States

This badge indicates the Principal Investigator has a proven record of excellence in the advancement of Theranostics.


Carolina Urologic Research Center

Myrtle Beach, South Carolina, United States

This badge indicates the Principal Investigator has a proven record of excellence in the advancement of Theranostics.


The Urology Place

San Antonio, Texas, United States

This badge indicates the Principal Investigator has a proven record of excellence in the advancement of Theranostics.


NorthShore University Health System

Glenview, Illinois 60026, United States

This badge indicates the Principal Investigator has a proven record of excellence in the advancement of Theranostics.


Urologic Specialists

Tulsa, Oklahoma 74146, United States

This badge indicates the Principal Investigator has a proven record of excellence in the advancement of Theranostics.


Intermountain Health

Utah, United States

This badge indicates the Principal Investigator has a proven record of excellence in the advancement of Theranostics.
BAMF Health

Grand Rapids, Michigan 49503, United States

This badge indicates the Principal Investigator has a proven record of excellence in the advancement of Theranostics.
Urology Clinics of North Texas

Dallas, Texas, United States

This badge indicates the Principal Investigator has a proven record of excellence in the advancement of Theranostics.
Corewell Health

Michigan, United States

This badge indicates the Principal Investigator has a proven record of excellence in the advancement of Theranostics.
Mayo Clinic - Jacksonville

Jacksonville, Florida, United States


Australia

St. Vincent's Hospital

Sydney, New South Wales, Australia

This badge indicates the Principal Investigator has a proven record of excellence in the advancement of Theranostics.


Princess Alexandra Hospital

Woolloongabba, Queensland, Australia

This badge indicates the Principal Investigator has a proven record of excellence in the advancement of Theranostics.


© 2021 XCancer Software LLC

Contact XCancer: 402-991-8468